Trial Profile
A study evaluating safety and efficacy of dolutegravir as a switch therapy in HIV patients responding to a first-line antiretroviral treatment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2016
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Raltegravir
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 30 Dec 2016 New trial record